FDA approves new lung cancer therapy for patients who develop resistance

(International Association for the Study of Lung Cancer) The International Association for the Study of Lung Cancer commends the US Food and Drug Administration's decision to grant accelerated approval for osimertinib (TagrissoTM), an oral medication for advanced non-small cell lung cancer patients with a specific epidermal growth factor receptor (EGFR) mutation (T790M) and following progression after previous EGFR inhibitor therapies.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Abstract Accumulating evidence suggests that microRNAs (miRNAs) has been proven to be a critical regulator in the tumor progression, of which miR-195-5p was reported to function as tumor suppressor in prostate cancer and oral squamous cell carcinoma. However, studies on the clinical significance and biological function of miR-195-5p in non-small cell lung cancer (NSCLC) were still unavailable. Here, we reported that the expression of miR-195-5p was decreased in NSCLC tissues and cell lines. Downregulation of miR-195-5p was significantly associated with TNM stage, tumor size and lymph node metastasis. The Kaplan-Me...
Source: Pathology Oncology Research - Category: Pathology Authors: Tags: Pathol Oncol Res Source Type: research
This article summarizes the milestones in the development of lorlatinib leading to the first global approval for this indication.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Abstract Valosine containing protein (VCP/p97) is a member of the AAA ATPase family involved in several essential cellular functions and plays an important role in the ubiquitin-mediated degradation of misfolded proteins. P97 has a significant role in maintaining the cellular protein homeostasis for tumor cell growth and survival and has been found overexpressed in many tumor types. No new molecule entities based on p97 target were approved in clinic. Herein, a series of novel pyrimidine structures as p97 inhibitors were designed and synthesized. After enzymatic evaluations, structure-activity relationships (SAR) ...
Source: Bioorganic and Medicinal Chemistry - Category: Chemistry Authors: Tags: Bioorg Med Chem Source Type: research
CONCLUSION: This S-1 and PTX cotherapy dose and schedule showed satisfactory efficacy with mild toxicities in elderly patients with advanced NSCLC. PMID: 30578309 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Authors: Corrales L, Scilla K, Caglevic C, Miller K, Oliveira J, Rolfo C Abstract The management of Non-Small Cell Lung Cancer (NSCLC) has changed dramatically in the last 10 years with an increase in the understanding of the biology and with the development of new and multiple treatments. Chemotherapy being the first systemic treatment used in the setting of advanced disease, proving benefit for patients over palliative care. With the identification of oncogenic drivers, innovative targeted therapies were developed and tested, leading to important changes in the management of certain patients and giving to some of...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
This study investigated correlations of the clinical outcomes of oral metronomic vinorelbine (VNR) with VNR pharmacokinetics and MDR1 polymorphisms.MethodsEighty-two patients with metastatic non-small cell lung cancer (NSCLC) unfit for standard chemotherapy were treated with VNR at the oral doses of 20 –30 mg every other day or 50 mg three times a week. They had a performance status (PS) ≤ 3, were>  70-year-old and drug-naïve or cisplatin-pretreated. MDR1 2677G >  T and 3435C >  T polymorphisms were analysed and blood concentrations of VNR an...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Afatinib is an oral irreversible epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) indicated in first-line treatment of advanced EGFR-mutant (EGFRm+) non-small cell lung cancer (NSCLC). D...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Lung cancer is the most common cancer and the leading cause of cancer-related death worldwide [1]. Non-small cell lung cancer (NSCLC) accounts for 85% of new diagnosed cases. Most patients are diagnosed with an unresectable disease and about 22% have a locally advanced disease [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Abstract We previously demonstrated that capsazepine (CPZ), a synthetic transient receptor potential Vanilloid subtype 1 (TRPV1) antagonist, has significant anti-cancer effects in vivo. The purpose of this study was to develop more potent analogs based upon CPZ pharmacophore and structure-activity relationships (SAR) across analogs. We generated 30 novel compounds and screened for their anti-proliferative effects in cultured HeLa cervical cancer cells. Cell viability assays identified multiple compounds with IC50s 
Source: Bioorganic and Medicinal Chemistry - Category: Chemistry Authors: Tags: Bioorg Med Chem Source Type: research
Tosedostat represents a next generation oral aminopeptidase inhibitor prodrug that has recently demonstrated promising activity in elderly patients with relapsed and refractory acute myeloid leukemia (AML). This prodrug is bio-activated to its hydrophilic active metabolite by intracellular esterases including carboxylesterase 1 (CES1) hence enhancing its cellular retention and promoting targeting of multiple aminopeptidases.Aminopeptidase inhibition provokes an amino acid deprivation response, inhibition of mTOR activity and blockade of protein synthesis. The fact that CES1 also has an important physiological function in c...
Source: Blood - Category: Hematology Authors: Tags: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster III Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Food and Drug Administration (FDA) | Grants | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Study